Osiris Therapeutics’ profit soars in 4Q

Osiris Therapeutics Inc., of Columbia, a biotechnology company that uses adult stem cell therapy to treat damaged tissue, reported fourth-quarter net income of $49.8 million, or $1.44 per diluted share, versus a loss of $2.6 million, or 8 cents per diluted share, a year earlier, outstrippng the estimates of analysts polled by Thomson Reuters who expected earnings of 65 cents per share.

Leave a Reply

Your email address will not be published. Required fields are marked *